Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
421-440 of 1,307 trials

Severe Hemophilia A: Continued Access to Efanesoctocog Alfa

We are providing ongoing treatment access for patients with severe hemophilia A who completed a previous trial with efanesoctocog alfa. The study aims to gather more information on its safety and effectiveness in preventing and treating bleeding episodes.

Haemophilia AConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Teicoplanin for Infection Prevention in Pediatric AML

We are studying whether teicoplanin can help prevent serious infections in children newly diagnosed with acute myeloid leukemia. This trial will assess its safety and effectiveness during their treatment.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesOncology

Atopic Dermatitis: Long-Term Study of Amlitelimab

We are evaluating the long-term safety and effectiveness of amlitelimab for individuals with moderate to severe atopic dermatitis who have participated in earlier studies. This research aims to better understand how the treatment works over time.

Atopic Dermatitis>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Severe Depression: Ketamine vs. Placebo

We are studying whether adding ketamine to venlafaxine helps hospitalized patients with severe depression feel better faster than a placebo. We’re also looking at its effects on hospital stay and side effects.

Major Depressive Disorder1-2 yearsConfirmation phase (III)Investigational MedicinesPsychiatry

Bipolar Depression: New Treatment Approach

We are investigating whether a six-week intensified medication plan helps people with bipolar depression who didn't respond to their first treatment. We’ll compare this new approach to standard care to see which is more effective.

Bipolar Depression≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Heart Health: Ticagrelor with Aspirin After CABG

We are studying whether adding ticagrelor to aspirin helps reduce heart-related events in patients after coronary artery bypass surgery. This trial also looks at the risk of bleeding and graft failure.

Coronary Artery Disease>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Lennox-Gastaut Syndrome: Carisbamate Treatment Study

We are investigating whether carisbamate can help reduce drop seizures in children and adults with Lennox-Gastaut Syndrome. This study will also look at the safety and tolerability of the medication.

Lennox-Gastaut Syndrome3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Major Depressive Disorder: New Treatment Approach

We are studying whether a six-week intensified medication treatment helps people with major depressive disorder who didn't respond to their first treatment. The goal is to see if this new approach improves symptoms and overall well-being compared to standard care.

Major Depressive Disorder≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePsychiatry

Breast Cancer: Lower Dose of CDK 4/6-Inhibitors

We are studying whether a lower initial dose of a cancer medication is effective for older breast cancer patients compared to the standard dose. This trial aims to improve treatment outcomes and quality of life for vulnerable patients.

Advanced Breast Cancer>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteGastroenterologyGynecology and ObstetricsOncology

Dapagliflozin for Heart Protection in Breast Cancer Patients

We are studying whether dapagliflozin can help prevent heart problems in breast cancer patients receiving chemotherapy. This trial compares its effects to a placebo over 12 months.

Secondary CardiomyopathyInvasive Breast Cancer3-6 monthsConfirmation phase (III)Standard MedicinesCardiologyOncology

Metastatic Colorectal Cancer: Atezolizumab with FOLFOXIRI

We are studying whether adding Atezolizumab to standard treatment helps patients with unresectable metastatic colorectal cancer live longer without disease progression. The trial also looks at the safety and quality of life for participants.

Metastatic Colorectal Cancer3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Ocular Myasthenia Gravis: Corticosteroids and Rituximab Treatment

We are studying whether immediate corticosteroid therapy combined with rituximab can help prevent worsening symptoms in patients with ocular myasthenia gravis. This trial looks at various health outcomes over two years.

Myasthenia Gravis6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyRheumatology

Rheumatoid Arthritis: New Biosimilar Drug Study

We are comparing a new biosimilar drug to Orencia® for patients with moderate to severe rheumatoid arthritis already taking methotrexate. The study will look at effectiveness, safety, and how the body reacts to the treatment.

Rheumatoid Arthritis1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteRheumatology

Multiple Myeloma: Etentamig Treatment Study

We are studying a new medication, Etentamig, for adults with relapsed or refractory multiple myeloma who have already received multiple treatments. The goal is to see if it is more effective and safe compared to standard therapies.

Relapsed or Refractory Multiple MyelomaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Heart Failure: Colchicine and Thiamine Study

We are studying whether colchicine and thiamine can help improve heart health in people with heart failure due to ischemic heart disease. The trial looks at their effects on serious heart-related events and hospital visits.

Heart Failure>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Metastatic Uveal Melanoma: IDE196 and Crizotinib Combination

We are studying a new combination treatment for HLA-A2 negative metastatic uveal melanoma to see if it works better than current options. The trial will also evaluate the safety and quality of life for participants.

Uveal Melanoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOphthalmology

Non-Small Cell Lung Cancer: Tiragolumab and Atezolizumab Study

We are evaluating the safety of a new treatment combining tiragolumab and atezolizumab for patients with certain stages of non-small cell lung cancer after surgery and chemotherapy. This study compares it to a placebo treatment to see how well it works.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Oncology

Prostate Cancer: 12-Month Treatment Study

We are studying whether stopping a treatment for prostate cancer after 12 months is as effective as continuing it. This may help reduce side effects and costs for patients with low-volume metastatic castration-sensitive prostate cancer.

Low-Volume Metastatic Castration-Sensitive Prostate Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyUrology

Rectal Cancer Treatment: Comparing Therapies for Older Patients

We are studying whether a conventional treatment approach is safer and more effective than total neoadjuvant therapy for older patients with locally advanced rectal cancer. This trial will also look at quality of life and healthcare resource use.

Rectal Cancer6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Mantle-Cell Lymphoma: Glofitamab with Venetoclax and Zanubrutinib

We are studying a new treatment combination for patients with untreated or relapsed high-risk mantle-cell lymphoma. The trial aims to see if this combination works better than Venetoclax alone.

Mantle-Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesHematologyOncology